Shanghai Pharmaceuticals Holding Co. Ltd. Class A

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H carries a market capitalization of 72.65B, placing it among publicly traded companies globally. Its enterprise value stands at 97.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Pharmaceuticals Holding Co. Ltd. Class H's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H has 6.37B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H recorded 2.11B in income tax expense.

As of the close on October 22, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H's stock has declined approximately 11.62% over the past 52 weeks. The 50-day moving average sits at 11.23, while the 200-day moving average is 11.63.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H holds 53.15B in cash and equivalents against 61.24B in total debt, resulting in a net debt position of 15.29B. Total book value stands at 90.55B, with working capital of 55.43B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H paid dividends of 0.37 per share.